603-259-3700

North Country Health Consortium

North Country Primary Care Extension

 

AHECOn this page you'll find:

 

News Feeds

CDC: COCA

CDC Clinician Outreach and Communication Activity (COCA)

CDC's Clinician Outreach and Communication Activity (COCA) has developed partnerships with national clinician organizations to facilitate communication regarding disease outbreaks and terrorism events. CDC communicates with its clinician partners via monthly conference calls and weekly e-mail updates.

New: Health Alert Network (HAN) No. 407 - Rifampin/Penicillin-Resistant Strain of RB51 Brucella Contracted from Consumption of Raw Milk

The Texas Department of State Health Services, with assistance from CDC, is investigating Brucella RB51 exposures and illnesses that may be connected to the purchase and consumption of raw (unpasteurized) milk from K-Bar Dairy in Paradise, Texas. Symptoms of brucellosis can include: fever, sweats, malaise, anorexia, headache, fatigue, muscle & joint pain, and potentially more serious complications (e.g., swelling of heart, liver, or spleen, neurologic symptoms).

Posted on September 13, 2017 | 12:30 pm

New: Health Alert Network (HAN) No. 406 - Hurricane Harvey—Clinical Guidance for Carbon

Carbon monoxide (CO) is an odorless, colorless, poisonous gas that can cause sudden illness and death if present in sufficient concentration in the ambient air. During a significant power outage, persons using alternative fuel or power sources such as generators or gasoline powered engine tools such as pressure washers might be exposed to toxic CO levels if the fuel or power sources are placed inside or too close to the exterior of the building causing CO to build up in the structure. The purpose of this HAN advisory is to remind clinicians evaluating persons affected by the storm to maintain a high index of suspicion for CO poisoning.

Posted on September 9, 2017 | 9:30 pm

New: Health Alert Network (HAN) No. 405 - Increase in Reported cases of Cyclospora cayetanensis Infection, United States, Summer 2017

The Centers for Disease Control and Prevention (CDC), State and Local Health Departments, and the Food and Drug Administration (FDA) are investigating an increase in reported cases of cyclosporiasis. The purpose of this HAN Advisory is to notify public health departments and healthcare facilities and to provide guidance to healthcare providers of the increase in reported cases. Please disseminate this information to healthcare providers in hospitals and emergency rooms, to primary care providers, and to microbiology laboratories. Healthcare providers should consider a diagnosis of cyclosporiasis in patients with prolonged or remitting-relapsing diarrheal illness. Testing for Cyclospora is not routinely done in most U.S. laboratories, even when stool is tested for parasites. Healthcare providers must specifically order testing for Cyclospora, whether testing is requested by ova and parasite (O&P) examination, by molecular methods, or by a gastrointestinal pathogen panel test. Cyclosporiasis is a nationally notifiable disease; healthcare providers should report suspect and confirmed cases of infection to public health authorities.

Posted on August 7, 2017 | 2:00 pm

Upcoming COCA Call: July 27: Zika Virus: Updates to Clinical Guidance and Recommendations for Pregnant Women and Infants

CDC has updated its interim guidance for pregnant women with possible exposure to Zika virus to include separate recommendations for pregnant women with symptoms and pregnant women without symptoms. In addition, CDC recently released its latest findings from the Zika pregnancy and infant registries on pregnancy outcomes for pregnant women with Zika virus infection in the U.S. territories and has new updates for healthcare providers on pediatric ophthalmologic findings in infants with possible congenital Zika virus exposure. During this COCA Call, clinicians will learn about the recent updates to CDC’s interim guidance for pregnant women with possible exposure to Zika virus; hear about the latest findings on pregnancy outcomes in the U.S. territories, based on the Zika pregnancy and infant registries; and receive new information on pediatric ophthalmologic findings to assist in caring for patients based on currently available data.

Posted on July 24, 2017 | 11:00 am

COCA Digest: July 3, 2017

Posted on July 11, 2017 | 11:00 am

New: Health Alert Network (HAN) No. 404 - Patients Receiving Eculizumab (Soliris®) at High Risk for Invasive Meningococcal Disease Despite Vaccination

Eculizumab (Soliris®) recipients have a 1,000 to 2,000-fold greater risk of invasive meningococcal disease compared to the general U.S. population. The Food and Drug Administration (FDA)-approved prescribing information for eculizumab includes a black box warning for increased risk of meningococcal disease, and the Advisory Committee on Immunization Practices (ACIP) recommends meningococcal vaccination for all patients receiving eculizumab. Recent data show that some patients receiving eculizumab who were vaccinated with the recommended meningococcal vaccines still developed meningococcal disease, most often from nongroupable Neisseria meningitidis, which rarely causes invasive disease in healthy individuals.

Posted on July 7, 2017 | 11:00 am

COCA Digest: June 5, 2017

Posted on June 7, 2017 | 11:00 am

Upcoming COCA Call: May 24: Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

On May 17, 2017, the U.S. Food and Drug Administration (FDA) issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick of heelstick. During this COCA call, clinicians will learn the importance of lead testing for children and pregnant or lactating women, which patients may be impacted, and CDC’s recommendations for re-testing.

Posted on May 24, 2017 | 11:00 am

Health Alert Network (HAN) No. 403 - Potential for Falsely Low Blood Lead Test Results from LeadCare® Analyzers

The U.S. Food and Drug Administration (FDA) has issued a safety communication warning about the use of Magellan Diagnostics’ LeadCare® analyzers (LeadCare, LeadCare II, LeadCare Ultra and LeadCare Plus) with venous blood samples because they might result in falsely low test results. FDA is now advising that Magellan Diagnostics’ LeadCare® analyzers should no longer be used with venous blood samples. The safety alert does not apply to capillary blood lead test results collected by fingerstick or heelstick. The purpose of this Health Advisory is to notify state and local health departments, healthcare providers, and laboratories about CDC’s re-testing guidance in light of the safety alert.

Posted on May 17, 2017 | 9:00 am

Health Alert Network (HAN) No. 402 - Prolonged IgM Antibody Response in People Infected with Zika Virus: Implications for Interpreting Serologic Testing Results for Pregnant Women

In July 2016, CDC issued Interim Guidance for Health Care Providers Caring for Pregnant Women with Possible Zika Virus Exposure – United States, July 2016 (https://www.cdc.gov/mmwr/volumes/65/wr/mm6529e1.htm) that includes Zika virus immunoglobulin M (IgM) testing of pregnant women. However, some flavivirus infections can result in prolonged IgM responses (>12 weeks) that make it difficult to determine the timing of infection, especially in testing of asymptomatic people. Emerging epidemiologic and laboratory data indicate that Zika virus IgM can persist beyond 12 weeks in a subset of infected people. Therefore, detection of IgM may not always indicate a recent infection. Although IgM persistence could affect IgM test interpretation for all infected people, it would have the greatest effect on clinical management of pregnant women with a history of living in or traveling to areas with Zika virus transmission. Pregnant women who test positive for IgM antibody may have been infected with Zika virus and developed an IgM response before conception.

Posted on May 5, 2017 | 11:30 am

Health Alert Network (HAN) No. 401 - CDC Recommendations for Diagnosing and Managing Shigella Strains with Possible Reduced Susceptibility to Ciprofloxacin

This Health Advisory describes the identification of emerging Shigella strains with elevated minimum inhibitory concentration values for ciprofloxacin and outlines new recommendations for clinical diagnosis, management, and reporting, as well as new recommendations for laboratories and public health officials. Current interpretive criteria provided by the Clinical and Laboratory Standards Institute (CLSI) categorize these strains as susceptible to ciprofloxacin, which is a fluoroquinolone antibiotic and a key agent in the management of Shigella infections.

Posted on April 18, 2017 | 4:00 pm

COCA Email Updates: February 27, 2017 - March 13, 2017

Clinician Outreach and Communication Activity (COCA) Email Updates for February 27, 2017

Posted on March 13, 2017 | 9:00 am

SAMHSA

Substance Abuse and Mental Health Services Administration

Dr. McCance-Katz Appointed Assistant Secretary for Mental Health and Substance Use

Dr. Elinore F. McCance-Katz

Dr. McCance-Katz is the first Assistant Secretary for Mental Health and Substance Use. This position was created under the 21st Century Cures Act and will support behavioral health priorities including the opioid epidemic.

The post Dr. McCance-Katz Appointed Assistant Secretary for Mental Health and Substance Use appeared first on .

Posted on August 28, 2017 | 12:15 pm

Enhancing Trauma-Informed Approaches in Behavioral Healthcare

Teacher reading with children

SAMHSA seeks to integrate and enhance trauma-informed approaches in behavioral healthcare.

The post Enhancing Trauma-Informed Approaches in Behavioral Healthcare appeared first on .

Posted on August 11, 2017 | 3:30 am

Learning Center Brings Research to Practice

SAMHSA launched a redesigned NREPP Learning Center to support the use of research to improve behavioral health.

The post Learning Center Brings Research to Practice appeared first on .

Posted on August 7, 2017 | 6:30 am

Pain Management and Opioid Use with Veterans and Service Members

Military Father with Daughter

SAMHSA is working with the VA and DoD to enhance informed prescribing practices and prevent misuse with veterans and military service members that can result in overdose or death.

The post Pain Management and Opioid Use with Veterans and Service Members appeared first on .

Posted on June 12, 2017 | 5:00 am

“Making Each Day Count” for Prevention Week

Prevention Week Logo

This week individuals, communities, and organizations focused on "making each day count" - this year's theme for Prevention Week.

The post “Making Each Day Count” for Prevention Week appeared first on .

Posted on May 22, 2017 | 12:00 pm

Spotlights on Six Trauma-Informed Resilient Communities

Series highlights efforts underway to stimulate collaborations that address trauma.

The post Spotlights on Six Trauma-Informed Resilient Communities appeared first on .

Posted on May 16, 2017 | 12:00 pm

Transitioning from Prison to Community

Guidelines give behavioral health providers recommended supportive approaches to help people transition from prison successfully.

The post Transitioning from Prison to Community appeared first on .

Posted on April 6, 2017 | 10:00 am

Effects of Severe Weather on Behavioral Health

High Water Sign in Flooded Neighborhood

Major storms can affect mental health. Learn what to do before, during, and after a severe weather event. Get mental health tips and tools for planning effectively from SAMHSA’s free resources.

The post Effects of Severe Weather on Behavioral Health appeared first on .

Posted on January 25, 2017 | 4:00 am


Get The Medscape App ⇨
Pill Identifier • Drug Reference • Disease & Condition reference... and more

Preparedness and Response Public Health Advisory Council
Follow us on facebook Follow us on twitter